Abstract
Chemokines are key players in the attraction and activation of leukocytes and are thus implicated in the recruitment of immune cells at sites of infection and/or inflammation. They exert their action by binding to seven-transmembrane G protein-coupled receptors. The chemokine stromal cell-derived factor-1 (SDF-1)/CXCL12 represents the single natural ligand for the chemokine receptor CXCR4. CXCL12 possesses angiogenic properties and is involved in the outgrowth and metastasis of CXCR4-expressing tumors and in certain inflammatory autoimmune disorders, such as rheumatoid arthritis. CXCR4 expression on tumor cells is upregulated by hypoxia and angiogenic factors, such as vascular endothelial growth factor (VEGF). CXCR4 also acts as a co-receptor for entry of human immunodeficiency virus (HIV) in CD4+ T cells. Finally, CXCL12/CXCR4 interactions were shown to play an important role in the migration of hematopoietic stem cells and their progenitors from, and their retention within, the bone marrow, a site characterized by high CXCL12 expression. As such, CXCR4 inhibitors may be utilized to inhibit HIV-1 infection, tumor growth and metastasis and to mobilize hematopoietic stem cells from the bone marrow in the circulation, where they can be collected for autologous stem cell transplantation. Here, we discuss the different aspects of CXCL12/CXCR4 biology as well as the development and anti-cancer/stem cell mobilizing activity of CXCR4 antagonists.
Keywords: Angiogenesis, CXCL12, CXCR4, metastasis, progenitor cells, SDF-1, small molecule inhibitors, ELR, multiple myeloma, HUVEC, FGF-2, KR158, GL261, rheumatoid synovium, AMD3100, SCLC, Asp262, Glu288, non-Hodgkin's lymphoma, cholangiocarcinoma, acute lymphoblastic, acute myelogenous leukemia, bortezomib, melphalan, doxorubicin, dexamethasone, sorafenib, TN14003, MDA-MB-231, AMD070, WZ811, KRH-1636, KRH-3955, PRO2000, ALX40-4C, CTCE-9908, Plerixafor, BKT140, POL6326, TG-0054
Current Pharmaceutical Design
Title: CXCL12-CXCR4 Axis in Angiogenesis, Metastasis and Stem Cell Mobilization
Volume: 16 Issue: 35
Author(s): S. Liekens, D. Schols and S. Hatse
Affiliation:
Keywords: Angiogenesis, CXCL12, CXCR4, metastasis, progenitor cells, SDF-1, small molecule inhibitors, ELR, multiple myeloma, HUVEC, FGF-2, KR158, GL261, rheumatoid synovium, AMD3100, SCLC, Asp262, Glu288, non-Hodgkin's lymphoma, cholangiocarcinoma, acute lymphoblastic, acute myelogenous leukemia, bortezomib, melphalan, doxorubicin, dexamethasone, sorafenib, TN14003, MDA-MB-231, AMD070, WZ811, KRH-1636, KRH-3955, PRO2000, ALX40-4C, CTCE-9908, Plerixafor, BKT140, POL6326, TG-0054
Abstract: Chemokines are key players in the attraction and activation of leukocytes and are thus implicated in the recruitment of immune cells at sites of infection and/or inflammation. They exert their action by binding to seven-transmembrane G protein-coupled receptors. The chemokine stromal cell-derived factor-1 (SDF-1)/CXCL12 represents the single natural ligand for the chemokine receptor CXCR4. CXCL12 possesses angiogenic properties and is involved in the outgrowth and metastasis of CXCR4-expressing tumors and in certain inflammatory autoimmune disorders, such as rheumatoid arthritis. CXCR4 expression on tumor cells is upregulated by hypoxia and angiogenic factors, such as vascular endothelial growth factor (VEGF). CXCR4 also acts as a co-receptor for entry of human immunodeficiency virus (HIV) in CD4+ T cells. Finally, CXCL12/CXCR4 interactions were shown to play an important role in the migration of hematopoietic stem cells and their progenitors from, and their retention within, the bone marrow, a site characterized by high CXCL12 expression. As such, CXCR4 inhibitors may be utilized to inhibit HIV-1 infection, tumor growth and metastasis and to mobilize hematopoietic stem cells from the bone marrow in the circulation, where they can be collected for autologous stem cell transplantation. Here, we discuss the different aspects of CXCL12/CXCR4 biology as well as the development and anti-cancer/stem cell mobilizing activity of CXCR4 antagonists.
Export Options
About this article
Cite this article as:
Liekens S., Schols D. and Hatse S., CXCL12-CXCR4 Axis in Angiogenesis, Metastasis and Stem Cell Mobilization, Current Pharmaceutical Design 2010; 16 (35) . https://dx.doi.org/10.2174/138161210794455003
DOI https://dx.doi.org/10.2174/138161210794455003 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Proteome Analysis of Resting Human Neutrophils
Protein & Peptide Letters Mechanistic Approach to Understanding Psychosis Risk in Velocardiofacial Syndrome
Current Pediatric Reviews Which Biomarker is Useful to Evaluate as a Treatment Outcome in Spondyloarthritis?
Current Rheumatology Reviews Development and Optimization of Sustained Release Moxifloxacin Hydrochloride Loaded Nanoemulsion for Ophthalmic Drug Delivery: A 3<sup>2</sup> Factorial Design Approach
Micro and Nanosystems Anti-Cancer / Anti-Tumor
Current Bioactive Compounds Patent Selections
Recent Patents on Anti-Cancer Drug Discovery Current Status in the Discovery of Covalent Janus Kinase 3 (JAK3) Inhibitors
Mini-Reviews in Medicinal Chemistry Recent Insights into the Role of Prostanoids in Atherosclerotic Vascular Disease
Current Vascular Pharmacology Risk-Benefit Perspectives in COX-2 Blockade
Current Drug Safety Biomarker Approach Towards Rheumatoid Arthritis Treatment
Current Rheumatology Reviews The Influence of Different Disease States on Rituximab Pharmacokinetics
Current Drug Metabolism Nanosponges Encapsulated Phytochemicals for Targeting Cancer: A Review
Current Drug Targets Subject Index to Volume 2
Current Drug Targets - Inflammation & Allergy Editorial
Current Rheumatology Reviews Metabolomics as a Tool for Drug Discovery and Personalised Medicine. A Review
Current Topics in Medicinal Chemistry A Spectrum of Topics for 2019: Advances in Neuroinflammation, Oxidative Stress, Obesity, Diabetes Mellitus, Cardiovascular Disease, Autism, Exosomes, and Central Nervous System Diseases
Current Pharmaceutical Design High Resolution Molecular Analysis as Tool for Evaluation of Arthritis Pathology
Current Rheumatology Reviews Circadian Rhythms of Endothelial Nitric Oxide Synthase and Toll-like Receptors 2 Production in Females with Rheumatoid Arthritis Depending on NOS3 Gene Polymorphism
Reviews on Recent Clinical Trials The Yin and Yang of Inflammation
Current Molecular Medicine Antagonizing IL-6 in Ankylosing Spondylitis: A Short Review
Inflammation & Allergy - Drug Targets (Discontinued)